Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490307 | 0.90 | ELANE (0.82) | ELANE | |
| SCHEMBL561438 | 0.90 | ELANE (0.82) | ELANE | |
| Alvelestat SCHEMBL560757 | 0.85 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29519811 | 0.85 | ELANE (1.00) | ELANE | |
| Alvelestat SCHEMBL29740084 | 0.85 | ELANE (1.00) | ELANE | |
| SCHEMBL23925515 | 0.85 | ELANE (0.72) | ELANE | |
| Alvelestat SCHEMBL30179302 | 0.85 | ELANE (1.00) | ELANE | |
| SCHEMBL4126035 | 0.85 | ELANE (0.74) | ELANE | |
| SCHEMBL561367 | 0.85 | ELANE (0.71) | ELANE | |
| SCHEMBL561446 | 0.83 | ELANE (0.69) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | claimed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | claimed |
| EP-1663973-B3 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2019-09-25 | — | — | EP | disclosed |
| EP-1663973-B1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2013-12-25 | — | — | EP | disclosed |
| US-8501784-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2013-08-06 | — | — | US | disclosed |
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-8063073-B2 | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| EP-1663973-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026123-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035157-A1 | 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885 |
| US-20070203129-A1 | 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.